Matthews International Capital Management Lowers stake in China Biologic Products Inc (CBPO)

China Biologic Products Inc (CBPO) : Matthews International Capital Management reduced its stake in China Biologic Products Inc by 11.66% during the most recent quarter end. The investment management company now holds a total of 93,954 shares of China Biologic Products Inc which is valued at $10.8 Million after selling 12,400 shares in China Biologic Products Inc , the firm said in a disclosure report filed with the SEC on May 12, 2016.China Biologic Products Inc makes up approximately 0.50% of Matthews International Capital Management’s portfolio.

Other Hedge Funds, Including , Standard Life Investments Ltd added CBPO to its portfolio by purchasing 98,499 company shares during the most recent quarter which is valued at $11.3 Million. China Biologic Products Inc makes up approx 0.05% of Standard Life Investments Ltd’s portfolio. Bessemer Group Inc added CBPO to its portfolio by purchasing 525 company shares during the most recent quarter which is valued at $60,380. Blackrock Institutional Trust Company N.a. sold out all of its stake in CBPO during the most recent quarter. The investment firm sold 16,405 shares of CBPO which is valued $1.9 Million.Apex Capital Management boosted its stake in CBPO in the latest quarter, The investment management firm added 20,874 additional shares and now holds a total of 133,700 shares of China Biologic Products Inc which is valued at $15.6 Million. China Biologic Products Inc makes up approx 0.35% of Apex Capital Management’s portfolio.

China Biologic Products Inc opened for trading at $113.84 and hit $114.32 on the upside on Friday, eventually ending the session at $113.75, with a gain of 0.96% or 1.08 points. The heightened volatility saw the trading volume jump to 1,56,395 shares. Company has a market cap of $3,024,726 M.

On the company’s financial health, China Biologic Products Inc reported $1.09 EPS for the quarter, beating the analyst consensus estimate by $ 0.21 according to the earnings call on May 4, 2016. Analyst had a consensus of $0.88. The company had revenue of $85.60 million for the quarter.The company’s revenue was up 21.6% compared to the same quarter last year.

Many Wall Street Analysts have commented on China Biologic Products Inc. China Biologic Products Inc was Downgraded by Credit Suisse to ” Neutral” on Mar 1, 2016.

China Biologic Products Inc. (China Biologic) is a biopharmaceutical company. The Company is principally engaged in the research development manufacturing and sales of human plasma-based biopharmaceutical products in China. China Biologic has a product portfolio with over 20 different dosage forms of plasma products. The Company’s principal products are human albumin and immunoglobulin for intravenous injection (IVIG). China Biologic operates its business through two subsidiaries namely Shandong Taibang Biological Products Co. Ltd. and Guizhou Taibang Biological Products Co. Ltd. The Company also holds an interest in Xi’an Huitian Blood Products Co. Ltd. a plasma products company. Its products include human albumin human immunoglobulin IVIG thymopolypeptides injection human hepatitis B immunoglobulin human rabies immunoglobulin human tetanus immunoglobulin placenta polypeptide Factor VIII and human prothrombin complex concentrate (PCC).

Leave a Reply

China Biologic Products Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on China Biologic Products Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.